NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis $0.35 -0.03 (-7.83%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.35▼$0.4050-Day Range$0.32▼$0.8352-Week Range$0.28▼$15.60Volume294,498 shsAverage Volume406,038 shsMarket Capitalization$2.59 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Cingulate alerts: Email Address Cingulate MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside2,166.3% Upside$8.00 Price TargetShort InterestHealthy2.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.00 out of 5 stars 3.2 Analyst's Opinion Consensus RatingCingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCingulate has received no research coverage in the past 90 days.Read more about Cingulate's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.43% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently increased by 3.43%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CING. Previous Next 2.3 News and Social Media Coverage News SentimentCingulate has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Cingulate this week, compared to 3 articles on an average week.Search Interest5 people have searched for CING on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have not sold or bought any company stock.Percentage Held by Insiders17.71% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cingulate's insider trading history. Previous Next N/A Earnings and Valuation Read more about Cingulate's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Cingulate Stock (NASDAQ:CING)Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Read More CING Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CING Stock News HeadlinesJuly 25 at 2:52 PM | msn.comFyodor Dostoyevsky’s Five Principles of Personal FreedomJuly 25 at 2:52 PM | msn.comScientists Discover Brain Circuit That Could Explain How Placebos Ease PainJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 25 at 9:50 AM | msn.comNeuroscientists discover a key piece of the placebo effect puzzleJuly 24 at 4:22 PM | markets.businessinsider.comNew SPECT Study Unveils Significant Brain Activity Differences in DepressionJuly 24 at 4:22 PM | msn.comNeuroscientists discover brain circuitry of placebo effect for pain reliefJuly 23 at 4:30 PM | forbes.comWant To Be Kind To Your Brain? Choose ‘Multipurposing’ Over MultitaskingJuly 22, 2024 | msn.comBrain coupling patterns as predictive markers for psychosis in 22q11.2DSJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 21, 2024 | msn.comNew research uncovers brain hierarchies in music perceptionJuly 19, 2024 | msn.comNovel insights into how exercise functions as an antidepressantJuly 19, 2024 | msn.comHow different areas of the prefrontal cortex influence time variability in individual monkeysJuly 19, 2024 | msn.comUnique brain signal found linked to depression may help treat ‘lack of interest’ symptomJuly 19, 2024 | msn.comGood timing: Study unravels how our brains track timeJuly 19, 2024 | finance.yahoo.comCingulate Inc. (CINGW)July 19, 2024 | msn.comOur brain doesn’t perceive time as a clock. Instead, time flows with experiences, study findsJuly 18, 2024 | americanbankingnews.comShort Interest in Cingulate Inc. (NASDAQ:CING) Declines By 5.8%June 28, 2024 | globenewswire.comCingulate Announces Exercise of Warrants for $1.86 Million Gross ProceedsSee More Headlines Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CING CUSIPN/A CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+2,166.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,530,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-448.18% Debt Debt-to-Equity RatioN/A Current Ratio1.21 Quick Ratio1.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($5.88) per share Price / Book-0.06Miscellaneous Outstanding Shares7,345,000Free Float6,044,000Market Cap$2.59 million OptionableNot Optionable Beta-1.08 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Shane J. Schaffer Pharm.D. (Age 49)PharmD, CEO & Chairman of the Board Comp: $491.96kDr. Laurie A. Myers M.B.A. (Age 67)Ph.D., Executive VP & COO Comp: $415.17kDr. Matthew N. Brams M.D. (Age 60)Executive VP & Chief Medical Officer Comp: $244.79kMs. Jennifer L. Callahan C.P.A. (Age 53)Senior VP, CFO & Secretary Dr. Raul R. Silva M.D. (Age 66)Executive VP & Chief Science Officer Thomas DaltonVice President of Investor & Public RelationsMore ExecutivesKey CompetitorsEterna TherapeuticsNASDAQ:ERNANeuroSense TherapeuticsNASDAQ:NRSNRedHill BiopharmaNASDAQ:RDHLNuCanaNASDAQ:NCNATonix PharmaceuticalsNASDAQ:TNXPView All CompetitorsInsidersJennifer L CallahanBought 55 shares on 3/15/2024Total: $1,490.50 ($27.10/share)Jennifer L CallahanBought 250 shares on 9/15/2023Total: $3,350.00 ($13.40/share)Peter J WerthBought 91,157 shares on 8/11/2023Total: $1.00 M ($11.00/share)View All Insider Transactions CING Stock Analysis - Frequently Asked Questions How have CING shares performed this year? Cingulate's stock was trading at $7.65 at the start of the year. Since then, CING stock has decreased by 95.4% and is now trading at $0.3530. View the best growth stocks for 2024 here. How were Cingulate's earnings last quarter? Cingulate Inc. (NASDAQ:CING) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.60) EPS for the quarter, topping analysts' consensus estimates of ($2.20) by $1.60. When did Cingulate's stock split? Shares of Cingulate reverse split on Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an initial public offering on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CING) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
